CYP2E1 — Your Liver's Chemical Processor
CYP2E1 is a cytochrome P450 enzyme11 cytochrome P450 enzyme
Phase I drug-metabolizing enzyme that oxidizes substrates to prepare them for excretion
responsible for metabolizing ethanol, acetaminophen, volatile organic compounds, and
several anesthetic agents including sevoflurane and isoflurane. A key variant in its
upstream promoter region — rs2070672 (historically the RsaI/PstI polymorphism) —
alters how strongly the gene is expressed, shifting the balance between normal
detoxification and toxic metabolite generation.
The Mechanism
The rs2070672 SNP sits approximately 2 kilobases upstream of the CYP2E1
transcription start site in the 5' regulatory region. The reference A allele
(c1 haplotype) and the alternate G allele (c2 haplotype) affect transcription
factor binding at the promoter. The c2 (G) allele is associated with
higher basal CYP2E1 mRNA expression22 higher basal CYP2E1 mRNA expression
~1.7-fold higher expression in c1/c2 heterozygotes versus c1/c1 homozygotes in non-drinkers; with alcohol, the induction is ~2.0-fold greater
and greater enzyme inducibility when substrates like ethanol or isoniazid are present.
This means c2 carriers metabolize substrates faster, generating more reactive
intermediates per unit time.
CYP2E1's two most important substrates for toxicity are acetaminophen and ethanol:
- Acetaminophen: CYP2E1 converts a small fraction (~5–10%) of each dose into
NAPQI33 NAPQI
N-acetyl-p-benzoquinone imine — the reactive electrophile responsible for centrilobular hepatocellular necrosis in acetaminophen overdose. Higher enzyme activity means more NAPQI per dose. - Ethanol: CYP2E1 is the microsomal ethanol-oxidizing system (MEOS), converting ethanol to acetaldehyde and generating reactive oxygen species (ROS) in the process. Chronic alcohol consumption itself upregulates CYP2E1 expression, amplifying the oxidative stress cycle.
The Evidence
Acetaminophen metabolism: A study by
Ueshima et al. (1996)44 Ueshima et al. (1996)
Ueshima Y et al. Acetaminophen metabolism in patients with different cytochrome P-4502E1 genotypes. Alcohol Clin Exp Res, 1996
found that c2/c2 individuals cleared acetaminophen at more than twice the rate of
c1/c1 homozygotes, while c1/c2 heterozygotes showed intermediate metabolism and
marked enzyme induction after alcohol exposure.
Anti-tuberculosis drug hepatotoxicity: Isoniazid is metabolized partly by CYP2E1
into reactive intermediates. A meta-analysis by
Wang et al. (2016)55 Wang et al. (2016)
Wang FJ et al. Update meta-analysis of the CYP2E1 RsaI/PstI and DraI polymorphisms and risk of antituberculosis drug-induced hepatotoxicity: evidence from 26 studies. J Clin Pharm Ther, 2016
(7,423 participants across 26 studies) found that the c1/c1 genotype (A/A at
rs2070672) was associated with significantly higher risk of anti-TB drug-induced
hepatotoxicity (OR 1.32, 95% CI 1.03–1.69), particularly in East Asians on
combination therapy. This counterintuitive finding — c1/c1 showing higher
hepatotoxicity risk — likely reflects the complex interplay between CYP2E1
inducibility and the specific toxicokinetics of isoniazid. A smaller clinical
study by Vuilleumier et al. (2006)66 Vuilleumier et al. (2006)
Vuilleumier N et al. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol, 2006
found that the *1A/*1A genotype (c1/c1) was significantly associated with
isoniazid-induced liver enzyme elevation (OR 3.4, 95% CI 1.1–12).
Alcoholic liver disease: A study in Caucasians by
Grove et al. (1998)77 Grove et al. (1998)
Grove J et al. The RsaI polymorphism of CYP2E1 and susceptibility to alcoholic liver disease in Caucasians. Pharmacogenetics, 1998
found that c2 allele carriers presented with alcoholic liver disease roughly 7 years
earlier (mean 42 vs. 49 years), often with equally advanced pathology. The
association was amplified in patients carrying the ADH3*2/*2 genotype, suggesting
gene-gene synergy in alcohol-related liver injury.
Hepatocellular carcinoma: A meta-analysis by
Liu et al. (2014)88 Liu et al. (2014)
Liu W et al. CYP2E1 gene polymorphism and alcohol drinking on the risk of HCC: a meta-analysis. Mol Biol Rep, 2014
found no standalone CYP2E1 genotype-HCC association, but when combined with
alcohol exposure, the c2 variant allele was associated with OR 2.88 (95% CI 1.25–6.60).
Practical Actions
The key clinical contexts for this variant are:
Acetaminophen dosing: Both genotypes face risk at high doses, but c2 carriers generate reactive NAPQI more rapidly. Strict adherence to dosing limits is especially important. Combining acetaminophen with alcohol (even moderate amounts) dramatically increases NAPQI production regardless of genotype.
Isoniazid/anti-TB therapy: Paradoxically, c1/c1 individuals show higher hepatotoxicity risk from isoniazid — liver function monitoring during TB treatment is warranted regardless of genotype, but c1/c1 individuals may need more frequent checks.
Anesthesia: CYP2E1 is the principal enzyme defluorinating sevoflurane and isoflurane. Altered expression may influence post-operative fluoride accumulation and anesthetic metabolism, particularly with repeated exposures.
Occupational chemical exposure: CYP2E1 activates benzene, vinyl chloride, and other volatile organic compounds into genotoxic intermediates. G allele carriers with higher basal expression may face increased occupational chemical toxicity with sustained VOC exposure.
Interactions
rs2070672 is in strong linkage disequilibrium with rs2031920, the other key CYP2E1 5' flanking variant (RsaI site). These two SNPs form the c1/c2 haplotype block and are often studied together — their combined haplotype status is a more reliable predictor of CYP2E1 expression than either SNP alone. The G allele at rs2070672 alone should be interpreted in the context of the full CYP2E1 5' haplotype. The alcohol-interaction effects at this locus also interact with ADH1B/ADH1C (alcohol dehydrogenase) variants — carriers of both low-activity CYP2E1 and high-activity ADH genotypes may have distinct alcohol-exposure profiles.